cnot1 Antibody

What is CNOT1 and what are its primary cellular functions?

CNOT1 serves as the scaffolding component of the CCR4-NOT complex, one of the major cellular mRNA deadenylases. This complex is involved in multiple cellular processes including bulk mRNA degradation, miRNA-mediated repression, translational repression during translational initiation, and general transcription regulation . CNOT1 facilitates the interaction between the catalytic complex module and diverse RNA-binding proteins, mediating the complex recruitment to selected mRNA 3'UTRs .

The protein plays crucial roles in:

• Degradation of AU-rich element (ARE)-containing mRNAs through association with ZFP36

• Recruitment of the CCR4-NOT complex to miRNA targets and to the RISC complex via association with TNRC6A, TNRC6B, or TNRC6C

• Transcriptional repression, particularly of ligand-dependent transcriptional activation by nuclear receptors

• Maintenance of embryonic stem (ES) cell identity

Recent research has also revealed CNOT1's involvement in regulating circadian behavior through Per2 mRNA decay, demonstrating its significance in chronobiology .

What is the structure of CNOT1 and how does it relate to antibody targeting?

CNOT1 is a large protein with multiple functional domains that can be targeted by different antibodies. The protein exists in several isoforms, with isoform one being approximately 267 kDa and isoform four about 173 kDa . Commercial antibodies target different regions of the protein:

*Immunogen sequence: ALLQINTSWHTLRHELISTLMPIFLGNHPNSAIILHYAWHGQGQSPSIRQLIMHAMAEWYRMGEQYDQAKLSRILDVAQDLKALSMLLNGT

When selecting an antibody, researchers should consider which domain of CNOT1 they wish to study, as different antibodies may reveal different aspects of CNOT1 function or interaction.

How should I select the appropriate CNOT1 antibody for my specific research application?

Selection of the optimal CNOT1 antibody depends on several critical factors:

• Experimental application: Different antibodies are validated for specific applications. For example, ab234642 is suitable for IHC-P and ICC/IF, while CAB5969 is validated for WB, IF/ICC, and ELISA .

• Target species: Confirm cross-reactivity with your experimental model. Most CNOT1 antibodies react with human samples, but some also work with mouse models. The PA5-62024 antibody shows 100% sequence identity with mouse and rat orthologs .

• Epitope location: Consider whether specific domains or regions of CNOT1 are critical to your research. Antibodies targeting different regions may yield different results based on protein conformation, interactions, or post-translational modifications.

• Clonality: Polyclonal antibodies like ab234642 offer broader epitope recognition but potentially more background, while monoclonal antibodies provide higher specificity for a single epitope .

• Validation data: Review immunohistochemistry images, Western blot results, and other validation data provided by manufacturers to ensure the antibody performs as expected in contexts similar to your experimental system.

What validation steps should I perform before using a CNOT1 antibody in critical experiments?

Thorough validation is essential for ensuring reliable results with CNOT1 antibodies:

• Positive and negative controls: Test the antibody on samples known to express CNOT1 (e.g., U-87MG, 293T, or LO2 cells) and compare with negative controls .

• Knockdown/knockout validation: Compare antibody signal between wild-type samples and those with reduced CNOT1 expression, such as the heterozygous Cnot1+/− mouse model (complete knockout is embryonically lethal at E6.5) .

• Western blot analysis: Confirm the antibody detects bands of expected molecular weight (approximately 267 kDa for isoform one and 173 kDa for isoform four) .

• Cross-reactivity testing: Ensure specificity by testing for cross-reactivity with other CCR4-NOT complex components.

• Dilution optimization: Test a range of antibody dilutions to determine optimal signal-to-noise ratio for your specific application. For example, CAB5969 is recommended at 1:200-1:2000 for Western blot and 1:50-1:200 for IF/ICC .

What are the optimal conditions for using CNOT1 antibodies in Western blot experiments?

For optimal Western blot results with CNOT1 antibodies:

• Sample preparation: Due to CNOT1's large size (~267 kDa), use low percentage (6-8%) SDS-PAGE gels or gradient gels. Consider adding phosphatase inhibitors to preserve potential phosphorylation states.

• Transfer conditions: Use wet transfer methods with extended transfer times (overnight at low voltage) to ensure complete transfer of large proteins.

• Blocking conditions: 5% non-fat dry milk or BSA in TBST for 1-2 hours at room temperature is typically effective.

• Antibody dilutions: Follow manufacturer recommendations, typically ranging from 1:200 to 1:2000 for primary antibody incubation. CAB5969, for example, works effectively at 1:200-1:2000 dilution for Western blot .

• Incubation times: For such a large protein, longer primary antibody incubation (overnight at 4°C) often yields better results.

• Detection method: HRP-conjugated secondary antibodies with enhanced chemiluminescence detection work well. Given CNOT1's size, extended exposure times may be necessary.

• Controls: Include positive control lysates from cells known to express CNOT1, such as U-87MG, 293T, or LO2 cell lines .

How can I optimize immunofluorescence protocols for detecting CNOT1 in different cell types?

Optimizing immunofluorescence protocols for CNOT1 detection requires:

• Fixation method: 4% paraformaldehyde for 15-20 minutes typically preserves CNOT1 structure while maintaining cellular architecture.

• Permeabilization: Use 0.1-0.3% Triton X-100 in PBS for 10 minutes to ensure antibody access to nuclear CNOT1.

• Blocking solution: 5-10% normal serum (matching the species of the secondary antibody) with 1% BSA in PBS for 1 hour.

• Antibody dilution: Follow manufacturer recommendations; for example, ab234642 is effective at 1:100 dilution for ICC/IF, while CAB5969 works at 1:50-1:200 .

• Cell-specific considerations:

  • For neuronal cells: Longer permeabilization may be needed

  • For stem cells: Lower concentrations of detergents to preserve delicate structures

  • For highly dividing cells: Consider cell cycle stage when interpreting nuclear localization patterns

• Co-localization studies: CNOT1 can be co-stained with markers for P-bodies or stress granules to study its role in mRNA decay pathways.

• Signal amplification: For low abundance detection, consider using fluorescent secondary antibodies with signal amplification systems.

U-251 MG cells stained with ab234642 (1:100 dilution) show clear CNOT1 localization patterns that can serve as a positive control for optimization .

How can I investigate CNOT1's interactions within the CCR4-NOT complex?

To study CNOT1's interactions within the CCR4-NOT complex:

• Co-immunoprecipitation (Co-IP): Use CNOT1 antibodies to pull down the protein and its interacting partners. Anti-CNOT3 antibodies can also be used to pull down the entire CCR4-NOT complex, including CNOT1, CNOT3, CNOT6L, CNOT7, and CNOT8 subunits .

• Proximity ligation assay (PLA): This technique can visualize and quantify protein-protein interactions between CNOT1 and other complex components within intact cells.

• RNA immunoprecipitation (RIP): As demonstrated in research, anti-CNOT3 antibodies can be used to immunoprecipitate the CCR4-NOT complex along with interacting RNAs. This approach has revealed significant enrichment of target mRNAs such as Per2 (19-fold enrichment) and Bmal1 (7-fold enrichment) .

• Fluorescence resonance energy transfer (FRET): Tag CNOT1 and potential interaction partners with appropriate fluorophores to visualize direct interactions in living cells.

• Crosslinking mass spectrometry: This can identify specific residues involved in interactions between CNOT1 and other components of the complex.

• Yeast two-hybrid screening: While more traditional, this approach can still identify novel interaction partners.

These methods can help determine how CNOT1's scaffolding function facilitates the interaction between the catalytic complex module and diverse RNA-binding proteins that mediate complex recruitment to specific mRNA 3'UTRs .

What experimental approaches are effective for studying CNOT1's role in mRNA degradation?

To investigate CNOT1's function in mRNA degradation:

• mRNA stability assays: Measure half-lives of target mRNAs in conditions of CNOT1 knockdown or using heterozygous Cnot1+/− models compared to wild-type controls .

• Deadenylation assays: Use RNase H-treated RNA samples to monitor poly(A) tail lengths in the presence or absence of functional CNOT1.

• RNA-IP followed by qPCR: This approach can identify direct mRNA targets of the CNOT1-containing CCR4-NOT complex. Research has shown that anti-CNOT3 immunoprecipitates can be used to detect enrichment of target mRNAs like Per2 and Bmal1 .

• Tethering assays: Artificially tethering CNOT1 to reporter mRNAs can assess its sufficiency to induce degradation.

• CRISPR-Cas9 genome editing: Generate CNOT1 mutants affecting specific domains to dissect their contributions to mRNA decay.

• Transcriptome analysis: RNA-seq following CNOT1 perturbation can reveal global effects on mRNA abundance and stability.

• Microscopy techniques: Visualize co-localization of CNOT1 with mRNA decay factors in P-bodies or stress granules using appropriate antibodies.

These approaches can help understand how CNOT1 contributes to the degradation of ARE-containing mRNAs through association with factors like ZFP36 .

How should I design experiments to investigate CNOT1's role in circadian rhythm regulation?

Based on recent research linking CNOT1 to circadian rhythm regulation through Per2 mRNA decay , consider these experimental approaches:

• Temporal expression profiling: Measure CNOT1 expression over 24-hour periods in circadian-relevant tissues. Research shows that Cnot1 mRNA levels remain constant throughout the circadian day in the suprachiasmatic nucleus (SCN), unlike oscillating clock genes like Per1 .

• In situ hybridization: [33P] radiolabeled UTP in situ hybridization can be used to examine Cnot1 expression at different circadian time points (e.g., CT4 and CT12) in the SCN and other brain regions .

• Genetic models: Use heterozygous Cnot1+/− mice (complete knockouts are embryonically lethal) to study the effects of reduced CNOT1 levels on circadian behaviors and clock gene expression .

• RNA immunoprecipitation: Employ anti-CNOT3 antibodies to pull down the CCR4-NOT complex and associated mRNAs, followed by qPCR for circadian clock genes like Per2 and Bmal1. Research has demonstrated significant enrichment of these mRNAs (19-fold and 7-fold, respectively) in such immunoprecipitates .

• mRNA stability assays: Compare the decay rates of clock gene mRNAs between wild-type and Cnot1+/− mice to determine if CNOT1 differentially affects stability of specific clock components.

• Locomotor activity monitoring: Assess circadian behavioral outputs in Cnot1+/− mice compared to wild-type littermates under various lighting conditions.

• Tissue-specific conditional knockouts: Create tissue-specific CNOT1 deletions in circadian-relevant tissues to dissect regional contributions to circadian phenotypes.

How can I troubleshoot weak or non-specific signals when using CNOT1 antibodies?

When encountering issues with CNOT1 antibody performance:

• Weak signals:

  • Increase antibody concentration (within manufacturer guidelines)

  • Extend incubation times (overnight at 4°C for primary antibodies)

  • Use signal amplification methods like biotin-streptavidin systems

  • For Western blots, increase protein loading as CNOT1 may be expressed at low levels

  • Optimize sample preparation to prevent protein degradation (use fresh samples and complete protease inhibitor cocktails)

• Non-specific signals:

  • Increase blocking stringency (5-10% blocking agent)

  • Perform additional washing steps with higher detergent concentrations

  • Use more dilute antibody solutions (staying within recommended ranges)

  • Pre-absorb antibodies with cell/tissue lysates from species not being tested

  • Optimize secondary antibody dilutions

  • For polyclonal antibodies like ab234642, CAB5969, or PA5-62024, consider affinity purification

• High background in immunofluorescence:

  • Use longer blocking steps (2+ hours)

  • Include 0.1-0.3% Triton X-100 in antibody diluent

  • Reduce primary antibody concentration

  • Use centrifugation to clear antibody solutions before use

  • Consider autofluorescence quenching steps

• Western blot issues specific to CNOT1:

  • Use gradient gels (4-8% or 4-12%) to better resolve the large CNOT1 protein (~267 kDa)

  • Extend transfer times for complete transfer of high molecular weight proteins

  • Consider using PVDF membranes with 0.45 μm pore size rather than 0.2 μm

What controls should I include when working with CNOT1 antibodies?

Appropriate controls are essential for interpreting CNOT1 antibody results:

• Positive controls:

  • Cell lines known to express CNOT1, such as U-87MG, 293T, LO2, or U-251 MG cells

  • Tissue samples with established CNOT1 expression (e.g., kidney for ab234642)

  • Recombinant CNOT1 protein (particularly useful for testing antibody recognition of specific domains)

• Negative controls:

  • Primary antibody omission to assess secondary antibody specificity

  • Isotype control antibodies to evaluate non-specific binding

  • Pre-absorption of the antibody with immunizing peptide (if available)

  • CNOT1-depleted samples (siRNA knockdown or Cnot1+/− heterozygous models)

  • Tissues or cells lacking CNOT1 expression (though complete absence is rare due to its essential function)

• Specificity controls:

  • Western blot analysis confirming the expected molecular weight (~267 kDa for isoform one, ~173 kDa for isoform four)

  • Competing peptide blocks to confirm epitope specificity

  • Multiple antibodies targeting different CNOT1 regions to confirm consistent localization patterns

• Technical controls:

  • Loading controls for Western blots (high molecular weight housekeeping proteins)

  • Internal staining controls for immunohistochemistry/immunofluorescence

  • RNA extraction quality controls for studies examining CNOT1's impact on mRNA stability

How can CNOT1 antibodies contribute to understanding transcriptional regulation mechanisms?

CNOT1 antibodies can illuminate various aspects of transcriptional regulation:

• Chromatin immunoprecipitation (ChIP): Use CNOT1 antibodies to identify genomic regions where CNOT1 acts as a transcriptional repressor, particularly in the context of nuclear receptor signaling .

• ChIP-sequencing: Combine ChIP with next-generation sequencing to generate genome-wide binding profiles of CNOT1.

• Sequential ChIP (Re-ChIP): Determine co-occupancy of CNOT1 with other transcriptional regulators at specific genomic loci.

• Reporter gene assays: Assess the impact of CNOT1 on reporter gene expression, particularly for genes regulated by nuclear receptors, where CNOT1 is known to repress ligand-dependent transcriptional activation .

• Co-immunoprecipitation with transcription factors: Identify transcription factors that interact with CNOT1 to mediate its repressive effects.

• Immunofluorescence co-localization: Visualize the nuclear localization of CNOT1 in relation to transcriptional machinery components.

• Mass spectrometry following CNOT1 immunoprecipitation: Identify novel transcriptional regulators that associate with CNOT1.

These approaches can help understand how CNOT1 acts as a transcriptional repressor and how it represses ligand-dependent transcriptional activation by nuclear receptors .

What methodologies can I use to investigate CNOT1's role in embryonic stem cell identity maintenance?

To explore CNOT1's role in embryonic stem cell (ESC) biology:

• Conditional knockout systems: Given that complete CNOT1 knockout is embryonically lethal at E6.5, inducible or conditional knockout systems are essential for studying its role in ESCs .

• Partial depletion models: Use heterozygous Cnot1+/− models or carefully titrated siRNA/shRNA approaches to reduce but not eliminate CNOT1 function .

• Differentiation assays: Assess how CNOT1 depletion affects pluripotency marker expression and differentiation capacity of ESCs into various lineages.

• RNA-seq analysis: Compare transcriptomes of wild-type and CNOT1-depleted ESCs to identify genes whose expression depends on CNOT1.

• mRNA stability assays: Determine if CNOT1 selectively regulates stability of mRNAs encoding differentiation factors or pluripotency regulators.

• ChIP-seq analysis: Map CNOT1 binding sites across the ESC genome to identify direct transcriptional targets.

• Co-immunoprecipitation with pluripotency factors: Determine if CNOT1 physically interacts with core pluripotency transcription factors.

• Immunofluorescence: Use CNOT1 antibodies with pluripotency markers to assess co-localization patterns and expression changes during differentiation.

• Mass spectrometry: Identify ESC-specific interaction partners of CNOT1 that might contribute to its role in maintaining stem cell identity.

These approaches can provide insights into how CNOT1 contributes to the maintenance of embryonic stem cell identity, as mentioned in the functional descriptions .

How can CNOT1 antibodies be used to investigate the protein's role in disease pathology?

CNOT1 antibodies can be valuable tools for exploring disease associations:

• Tissue microarray analysis: Compare CNOT1 expression levels and patterns across normal and pathological tissues using immunohistochemistry.

• Patient-derived xenograft models: Use CNOT1 antibodies to assess protein expression and localization in these models that better recapitulate human disease.

• Single-cell analysis: Combine CNOT1 immunostaining with single-cell isolation techniques to examine heterogeneity within diseased tissues.

• Proximity ligation assays: Investigate altered protein interactions in disease states that may affect CNOT1's regulatory functions.

• Phospho-specific antibodies: Develop or use antibodies recognizing specific post-translational modifications of CNOT1 that may be altered in disease.

• Liquid biopsy analysis: Explore whether CNOT1 or its regulated targets can serve as biomarkers in circulating tumor cells or exosomes.

• Drug response studies: Assess how therapeutic interventions affect CNOT1 expression or localization in disease models.

The emerging links between CNOT1 dysregulation and various diseases, including cancer and neurological disorders, make this protein a promising target for therapeutic interventions and biomarker discovery .

What are the latest methodological advances for studying CNOT1's role in miRNA-mediated repression?

Recent methodological approaches to study CNOT1's involvement in miRNA pathways include:

• CLIP-seq (Crosslinking and Immunoprecipitation followed by sequencing): Use CNOT1 antibodies to identify RNAs directly bound by CNOT1 in the context of miRNA-mediated repression.

• Proximity labeling: Techniques like BioID or APEX2 fused to CNOT1 can identify proteins in proximity to CNOT1 within miRISC complexes.

• Live-cell imaging: Monitor the dynamics of CNOT1 recruitment to miRNA targets using fluorescently tagged CNOT1 and target mRNAs.

• Single-molecule approaches: Track individual molecules to observe CNOT1-mediated repression of miRNA targets in real-time.

• CRISPR screens: Identify genes that modify CNOT1's function in miRNA-mediated repression.

• Structural studies: Combine immunoprecipitation with cryo-EM to elucidate the structure of CNOT1 within miRISC complexes.

• Ribosome profiling: Assess how CNOT1 affects translation efficiency of miRNA targets at a transcriptome-wide level.

These approaches can help understand how CNOT1 mediates the recruitment of the CCR4-NOT complex to miRNA targets and to the RISC complex via association with TNRC6A, TNRC6B, or TNRC6C .

What are emerging trends in CNOT1 antibody applications for novel research directions?

Emerging trends in CNOT1 antibody applications include:

• Development of site-specific and modification-specific antibodies: New antibodies targeting specific phosphorylation, ubiquitination, or other post-translational modification sites on CNOT1 would enable deeper understanding of its regulation.

• Super-resolution microscopy applications: More sensitive antibodies compatible with techniques like STORM, PALM, or STED microscopy could reveal previously unobservable subcellular localization patterns and protein interactions.

• Mass cytometry (CyTOF) incorporation: Including CNOT1 antibodies in high-dimensional protein panels could reveal relationships between CNOT1 expression and various cellular states.

• Spatial transcriptomics integration: Combining CNOT1 antibody staining with spatial transcriptomics could correlate CNOT1 protein localization with mRNA expression patterns at single-cell resolution.

• Therapeutic targeting validation: Antibodies will play crucial roles in validating the efficacy of emerging therapeutic approaches targeting the CNOT1 pathway.

• Circadian biology applications: Building on recent findings connecting CNOT1 to circadian behavior regulation through Per2 mRNA decay, antibodies will help elucidate the temporal dynamics of this regulatory mechanism .

• Combinatorial epitope detection: Using multiple antibodies targeting different CNOT1 domains simultaneously could provide more comprehensive insights into protein conformation and interaction states.